LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

85.83 -0.74

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

84.5

Максимум

86.63

Ключови измерители
By Trading Economics
Приходи	-8.1M -56M
Продажби	2.9M 60M
EPS	-0.83
Марж на печалбата	-92.559
Служители	414
EBITDA	-9.7M -52M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+58.3% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-96M 5.8B
Предишно отваряне	86.57
Предишно затваряне	85.83

Настроения в новините

By Acuity

46%

54%

149 / 344 Класиране в Healthcare

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.06.2026 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8.06.2026 г., 15:41 ч. UTC

Значими двигатели на пазара

American Battery Shares Jump on Energy Department Victory

8.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rebound After Monday's Selloff -- Market Talk

8.06.2026 г., 23:37 ч. UTC

Пазарно говорене

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8.06.2026 г., 23:25 ч. UTC

Пазарно говорене

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8.06.2026 г., 23:25 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.06.2026 г., 21:57 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8.06.2026 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Agrees to Buy m3ter

8.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

8.06.2026 г., 19:22 ч. UTC

Пазарно говорене

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8.06.2026 г., 19:01 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8.06.2026 г., 18:52 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

8.06.2026 г., 18:52 ч. UTC

Пазарно говорене

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8.06.2026 г., 18:17 ч. UTC

Пазарно говорене

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8.06.2026 г., 17:32 ч. UTC

Пазарно говорене

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8.06.2026 г., 17:29 ч. UTC

Пазарно говорене

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8.06.2026 г., 17:29 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.06.2026 г., 16:55 ч. UTC

Придобивния, сливания и поглъщания

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8.06.2026 г., 16:54 ч. UTC

Придобивния, сливания и поглъщания

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8.06.2026 г., 16:40 ч. UTC

Пазарно говорене

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8.06.2026 г., 16:31 ч. UTC

Пазарно говорене

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8.06.2026 г., 16:27 ч. UTC

Пазарно говорене

Mexican Inflation Seen Easing in May -- Market Talk

8.06.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.06.2026 г., 16:03 ч. UTC

Придобивния, сливания и поглъщания

Orange Bought Stake From Lorca

8.06.2026 г., 16:01 ч. UTC

Придобивния, сливания и поглъщания

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8.06.2026 г., 16:01 ч. UTC

Придобивния, сливания и поглъщания

Orange Acquires 100% Ownership of MasOrange

8.06.2026 г., 15:58 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.06.2026 г., 15:58 ч. UTC

Пазарно говорене

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8.06.2026 г., 15:55 ч. UTC

Пазарно говорене

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8.06.2026 г., 15:41 ч. UTC

Пазарно говорене

Gold Falls Below 200-Day Moving Average -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

58.3% нагоре

12-месечна прогноза

Среден 136.77 USD 58.3%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

149 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.